Company / Shareholders' Equity
Alaunos Therapeutics, Inc. Shareholders' Equity History
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$2.1M
FY2025
5-year range
$2.1M / $124.0M
FY2021-FY2025
Trend
-67.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 4 consecutive years, from $124M in FY2021 to $2M in FY2025.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -53.5%.
Declined from $39M to $2M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -67.1%
- 5-Year CAGR
- -53.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- Alaunos Therapeutics, Inc.'s shareholders' equity has declined for 4 consecutive years.
- 5-year CAGR of -53.5%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 67.3% year-over-year.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.79 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.1M | -67.3% |
| FY2024 | $6.3M | -83.6% |
| FY2023 | $38.6M | -33.6% |
| FY2022 | $58.1M | -53.2% |
| FY2021 | $124.0M | +30.5% |
| FY2020 | $95.0M | +198.1% |
| FY2019 | -$96.8M | -25.2% |
| FY2018 | -$77.3M | -207.9% |
| FY2013 | $71.6M | +14221.4% |
| FY2012 | $500.0K | +0.0% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026